CN117264865A - Recombinant rhodococcus erythropolis and application thereof in compound synthesis - Google Patents
Recombinant rhodococcus erythropolis and application thereof in compound synthesis Download PDFInfo
- Publication number
- CN117264865A CN117264865A CN202311553921.6A CN202311553921A CN117264865A CN 117264865 A CN117264865 A CN 117264865A CN 202311553921 A CN202311553921 A CN 202311553921A CN 117264865 A CN117264865 A CN 117264865A
- Authority
- CN
- China
- Prior art keywords
- gene
- rhodococcus erythropolis
- recombinant
- synthesis
- carotenoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 65
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 64
- 241000187561 Rhodococcus erythropolis Species 0.000 title claims abstract description 61
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 103
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 64
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 64
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 241000316848 Rhodococcus <scale insect> Species 0.000 claims abstract description 26
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 claims abstract description 18
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 claims abstract description 18
- 235000011765 phytoene Nutrition 0.000 claims abstract description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 16
- 230000002829 reductive effect Effects 0.000 claims abstract description 16
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 claims abstract description 14
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 13
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 claims abstract description 12
- 150000001746 carotenes Chemical class 0.000 claims abstract description 11
- 235000005473 carotenes Nutrition 0.000 claims abstract description 11
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 27
- 108010024026 Nitrile hydratase Proteins 0.000 claims description 25
- 239000013612 plasmid Substances 0.000 claims description 20
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 16
- -1 amide compounds Chemical class 0.000 claims description 15
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 11
- 238000006703 hydration reaction Methods 0.000 claims description 11
- 238000010446 CRISPR interference Methods 0.000 claims description 8
- 229960003966 nicotinamide Drugs 0.000 claims description 8
- 235000005152 nicotinamide Nutrition 0.000 claims description 8
- 239000011570 nicotinamide Substances 0.000 claims description 8
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 7
- 239000013600 plasmid vector Substances 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 150000002118 epoxides Chemical class 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- WTOSNONTQZJEBC-UHFFFAOYSA-N erythrosin Chemical compound OC(=O)C1=CC=CC=C1C(C1C(C(=C(O)C(I)=C1)I)O1)=C2C1=C(I)C(=O)C(I)=C2 WTOSNONTQZJEBC-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 18
- 108090000790 Enzymes Proteins 0.000 abstract description 18
- 239000000049 pigment Substances 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 6
- 235000013923 monosodium glutamate Nutrition 0.000 description 6
- 239000004223 monosodium glutamate Substances 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 101150084750 1 gene Proteins 0.000 description 3
- 102000005486 Epoxide hydrolase Human genes 0.000 description 3
- 108020002908 Epoxide hydrolase Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 108010033272 Nitrilase Proteins 0.000 description 3
- 241000187693 Rhodococcus rhodochrous Species 0.000 description 3
- 101100061456 Streptomyces griseus crtB gene Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 101150011633 crtI gene Proteins 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710173432 Phytoene synthase Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150052745 crtM gene Proteins 0.000 description 1
- 101150085103 crtY gene Proteins 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 108060004506 lycopene beta-cyclase Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 108010001545 phytoene dehydrogenase Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/05—Oxidoreductases acting on the CH-CH group of donors (1.3) with a quinone or related compound as acceptor (1.3.5)
- C12Y103/05005—15-Cis-phytoene desaturase (1.3.5.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01032—15-Cis-phytoene synthase (2.5.1.32)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01096—4,4'-diapophytoene synthase (2.5.1.96)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present application relates to recombinant rhodococcus erythropolis and its use in the synthesis of compounds, carotenoid in the recombinant rhodococcus erythropolisGenes are reduced in expression or knocked out; the carotenoid synthesis genes with reduced expression or knockdown include genes encoding GGPP synthasecrtE‑1Gene encoding phytoene dehydrogenasecrtIGene encoding carotene synthesis-related membrane proteincrtMAnd genes encoding phytoene synthasecrtBAt least one of (2). The recombinant rhodococcus erythropolis does not affect the growth and enzyme production of rhodococcus erythropolis, and reduces pigment content.
Description
Technical Field
The application relates to the technical fields of genetic engineering and synthetic biology, in particular to recombinant rhodococcus erythropolis and application thereof in compound synthesis.
Background
Rhodococcus erythropolis is a gram-positive bacterium and has important applications in biocatalysis, biodegradation, biomass utilization and the like. At present, rhodococcus containing important industrial enzymes such as nitrile hydratase, nitrilase, amidase, transaminase, epoxide hydrolase and the like is widely used as a biocatalyst in the industrial production of important compounds such as amide, carboxylic acid, chiral medicine intermediates and the like. However, when preparing a target chemical with high concentration, the problems of overhigh concentration of a substrate or a product, exothermic reaction and the like easily cause rhodococcus cell rupture, release pigment, deepen the color of a product solution, influence the quality of the product and increase the post-treatment cost of the product. Therefore, the reduction of the pigment content in the rhodococcus cells is significant for improving the product quality of the rhodococcus cell catalytic products and reducing the production cost.
Carotenoids are a class of natural pigments composed of isoprenoid polymers, which are widely found in animals, plants, fungi, algae and bacteria, and are more commonly tetraterpenoids such as C40-skeleton lycopene, beta-carotene, zeaxanthin, astaxanthin, capsanthin, and the like. Most rhodococci synthesize relatively large amounts of natural carotenoids, so the colony color appears orange or red. The pigments released by rhodococcus in biocatalytic reactions are mainly carotenoids, but to date, there have been no reports on weakening the synthesis of rhodococcus pigments by genetic engineering.
Although the main pathways for carotenoid biosynthesis are largely clear, the key genes for carotenoid synthesis in most rhodococcus have not been clear, and particularly the pathways related to carotenoid synthesis in rhodococcus erythropolis have not been reported so far. Rhodococcus usually contains redundant gene sequences, sometimes there are multiple different genes encoding proteins with the same function, but their activities often differ greatly, and it is difficult to predict which gene plays a major role, which further increases the difficulty of identifying key genes.
Disclosure of Invention
Accordingly, there is a need in the present application for a recombinant rhodococcus erythropolis having reduced pigment synthesis, and its use in the synthesis of amides, carboxylic acids, and the like.
The specific technical scheme is as follows:
a recombinant rhodococcus erythropolis in which the carotenoid synthesis gene is reduced in expression or knocked out; the carotenoid synthesis genes with reduced expression or knockdown include genes encoding GGPP synthasecrtE-1Gene encoding phytoene dehydrogenasecrtIGene encoding carotene synthesis-related membrane proteincrtMAnd genes encoding phytoene synthasecrtBAt least one of (2).
In one embodiment, the carotenoid synthesis gene with reduced expression or knockdown comprises a gene encoding GGPP synthasecrtE-1And/or genes encoding phytoene dehydrogenasecrtI。
The recombinant rhodococcus erythropolis is applied to compound synthesis.
In one embodiment, the compound includes one or more of an amide compound, a carboxylic acid compound, a chiral epoxide compound, and a chiral amine compound.
Compared with the traditional technology, the application has the following beneficial effects:
the application analyzes and identifies the key genes synthesized with the carotenoid of the rhodococcus erythropolis, constructs different recombinant rhodococcus erythropolis with weakened carotenoid synthesis by inactivating the key genes synthesized with the carotenoid, and screens the recombinant rhodococcus erythropolis which does not influence the growth and enzyme production of the rhodococcus erythropolis and reduces the pigment content. Further the method is used for synthesizing compounds such as amides, carboxylic acids, chiral epoxides, chiral amines and the like, and the quality of the compounds is improved.
Drawings
FIG. 1 shows carotenoid synthesis gene distribution of Rhodococcus erythropolis;
FIG. 2 is a graph showing the effect of inhibiting various carotenoid synthesis genes on carotenoid content;
FIG. 3 is a graph showing the effect of inhibiting the growth of rhodococcus by different carotenoid synthesis genes;
FIG. 4 is a graph showing the effect of inhibiting different carotenoid synthesis genes on rhodococcus nitrile hydratase activity;
FIG. 5 shows the color comparison of recombinant bacteria TH-crtE1 and TH-control;
FIG. 6 shows a color comparison of acrylamide hydration liquid synthesized by recombinant bacteria TH-crtE1 and TH-control.
Detailed Description
In order to make the above objects, features and advantages of the present application more comprehensible, embodiments accompanied with the present application are described in detail below. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present application. This application is, however, susceptible of embodiment in many other forms than those described herein and similar modifications can be made by those skilled in the art without departing from the spirit of the application, and therefore the application is not to be limited to the specific embodiments disclosed below.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein in the description of the application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
In order to solve the problem that the pigment release of rhodococcus erythropolis affects the product quality of rhodococcus erythropolis cell catalytic products in the reaction process, the application firstly analyzes key genes for synthesizing rhodococcus erythropolis carotene by a bioinformatics technology, and comprises genes for encoding GGPP synthetasecrtE-1AndcrtE-2gene encoding phytoene dehydrogenasecrtIGene encoding carotene synthesis-related membrane proteincrtMGene encoding phytoene synthasecrtBCoding lycopene beta-cyclasecrtY. Different recombinant rhodococcus erythropolis with weakened pigment synthesis are constructed through gene inactivation (inhibition or knockout), and strains which do not influence the growth and enzyme production of the rhodococcus erythropolis and reduce the pigment content are obtained through screening. The method is used for synthesizing compounds such as amides, carboxylic acids, chiral epoxides, chiral amines and the like, and improves the quality of the compounds.
An embodiment of the present application provides a recombinant rhodococcus erythropolis having reduced pigment synthesis, wherein the carotenoid synthesis gene in the recombinant rhodococcus erythropolis is inhibited or knocked out by expression. Wherein the carotenoid synthesis gene whose expression is suppressed or knocked out includes a gene encoding GGPP synthasecrtE-1Gene encoding phytoene dehydrogenasecrtIGene encoding carotene synthesis-related membrane proteincrtMGene encoding phytoene synthasecrtBAt least one of (2).
In a specific example, the carotenoid synthesis gene whose expression is inhibited or knocked out includes a gene encoding GGPP synthasecrtE-1And/or genes encoding phytoene dehydrogenasecrtI. Make the following stepscrtE1Or (b)crtIThe inactivation of the gene can reduce the yield of carotenoid to different degrees, and has no negative effect on the growth and enzyme production of bacteria. Wherein,crtE1inactivation of the gene reduces carotenoid content by more than 95%, biomass (OD 460 The value) is improved by 11 percent, the enzyme activity of nitrile hydratase fermentation is improved by 6 percent, the fermentation liquor of the strain is used for synthesizing high-concentration acrylamide, the chromaticity of the obtained hydration liquor is obviously reduced,the product quality is improved. And (3) withcrtE1In contrast to the inactivation of the gene,crtE1andcrtIthe genes are inactivated at the same time, so that the enzyme activity of the nitrile hydratase is improved by 21%, and the carotenoid content is reduced by 57%.
In a specific example, the knockout includes knocking out part or all of the carotenoid synthesis gene.
In a specific example, a gene encoding GGPP synthasecrtE-1The nucleotide sequence of (a) is shown as SEQ ID NO. 1, and/or a gene encoding phytoene dehydrogenasecrtIThe nucleotide sequence of (2) is shown as SEQ ID NO. 3, and/or the gene for encoding carotene synthesis related membrane proteincrtMThe nucleotide sequence of (a) is shown as SEQ ID NO. 4, and/or a gene encoding phytoene synthasecrtBThe nucleotide sequence of (2) is shown as SEQ ID NO. 5.
In a specific example, a genetically stable recombinant strain is constructed by knocking out a carotenoid synthesis gene, and the method for knocking out the carotenoid synthesis gene includes a homologous recombination double crossover method.
In a specific example, the method for constructing the recombinant rhodococcus erythropolis by using the homologous recombination double exchange method comprises the following steps of a-b:
and a step a, connecting an upstream homologous sequence and a downstream homologous sequence of the carotenoid synthesis gene into a suicide plasmid vector to obtain the recombinant suicide plasmid vector.
Primers are designed according to the upstream and downstream sequences of the carotenoid synthesis gene to amplify the upstream and downstream homologous sequences of the carotenoid synthesis gene, respectively.
And b, introducing the recombinant suicide plasmid vector into rhodococcus, and screening to obtain recombinant rhodococcus.
In a specific example, the method of screening comprises a first round of screening with an antibiotic-containing plate to obtain a first recombinant bacterium, and a second round of screening with a sucrose-containing plate to obtain a recombinant rhodococcus erythropolis.
Alternatively, the suicide plasmid vector comprises pK18mobsacB.
In a specific example, the method of reducing carotenoid synthesis gene expression comprises one or more of CRISPRi technology, antisense RNA technology, RNA interference, and promoter attenuation methods.
The CRISPRi technology inhibits transcription of target DNA through targeted combination of dCAS9-sgRNA complex and the target DNA to inhibit expression of the target gene. The dCas9-sgRNA complex can inhibit transcription of target DNA in two ways: (1) Transcription initiation is inhibited by preventing RNA polymerase from binding to the DNA promoter. (2) inhibition of transcriptional elongation by steric hindrance.
In a specific example, small molecule RNAs used in RNA interference techniques include miRNA, siRNA, dsRNA and shRNA.
In a specific example, a method of constructing a recombinant rhodococcus erythropolis using CRISPRi technology includes introducing a vector containing a dCas9 gene and a vector containing sgrnas targeting carotenoid synthesis genes into rhodococcus erythropolis to construct a recombinant rhodococcus erythropolis.
The two domains HNH and RuvC of the CRISPR/Cas9 protein with endonuclease activity are subjected to H840A and D10A site-directed mutagenesis respectively, so that dCAS9 protein losing endonuclease activity is obtained.
In a specific example, a gene encoding GGPP synthetase is targetedcrtE-1The recognition sequence of sgrnas of (a): GGCGTCCTCCTGGTCGTGTG (nucleotide sequence at positions 5-24 of SEQ ID NO: 11);
targeting genes encoding phytoene dehydrogenasecrtIThe recognition sequence of sgrnas of (a): CGACGGTCGCCTCGCGTTCG (nucleotide sequence 5-24 of SEQ ID NO: 15);
gene encoding carotene synthesis related membrane proteincrtMThe recognition sequence of sgrnas of (a): TCCGGGGGACGCTGCTGTTC (nucleotide sequence 5-24 in SEQ ID NO: 17);
gene encoding phytoene synthasecrtBThe recognition sequence of sgrnas of (a): ATAGTACGTCCGGCCGTGCG (nucleotide sequence at positions 5-24 of SEQ ID NO: 19).
An embodiment of the application also provides application of the recombinant rhodococcus erythropolis in compound synthesis. In one specific example, the compound includes one or more of an amide compound, a carboxylic acid compound, a chiral epoxide compound, and a chiral amine compound.
In a specific example, the recombinant rhodococcus erythropolis includes an exogenous plasmid carrying a gene encoding an exogenous enzyme. Exogenous plasmid carrying exogenous enzyme coding gene is introduced into recombinant rhodococcus erythropolis to express exogenous enzyme, and the exogenous enzyme is used for catalyzing substrate to synthesize target compound, so that the quality and yield of the compound are improved.
In one specific example, the exogenous enzyme includes one or more of a nitrilase, a nitrile hydratase, a transaminase, and/or an epoxide hydrolase.
Specifically, carboxylic acid compounds can be synthesized by utilizing nitrilase to catalyze, chiral epoxide can be synthesized by utilizing epoxide hydrolase to catalyze, chiral amine compounds can be synthesized by utilizing aminotransferase to catalyze, and amide compounds can be synthesized by utilizing nitrile hydratase to catalyze.
In one specific example, the amide-based compound includes acrylamide and/or nicotinamide.
In a specific example, the method of acrylamide or nicotinamide synthesis comprises the steps of:
expressing nitrile hydratase by utilizing the genome of the recombinant rhodococcus erythropolis and/or expressing nitrile hydratase by introducing exogenous plasmid carrying nitrile hydratase encoding gene into the recombinant rhodococcus erythropolis;
the nitrile hydratase is used for catalyzing the hydration reaction of acrylonitrile or 3-cyanopyridine to synthesize acrylamide or nicotinamide.
In one specific example, the temperature of the hydration reaction is 15 ℃ to 45 ℃. Optionally, the temperature of the hydration reaction is 18-25 ℃.
In a specific example, the method for synthesizing acrylamide or nicotinamide comprises the steps of (1) to (3):
and (1) preparing the seed solution of the recombinant rhodococcus erythropolis.
In a specific example, the recombinant rhodococcus erythropolis may also carry an exogenous plasmid encoding a gene for a nitrile hydratase.
In one embodiment showIn examples, the seed culture medium used for preparing the seed solution of the recombinant rhodococcus erythropolis comprises glucose 10 g/L-50 g/L, yeast extract 1 g/L-4 g/L, peptone 1 g/L-10 g/L, KH 2 PO 4 0.2 g/L -3 g/L,K 2 HPO 4 0.2 g/L -3 g/L,MgSO 4 ·7H 2 O0.2 g/L-3 g/L and monosodium glutamate 1 g/L, and pH value is 7.0-7.5.
And (2) preparing the fermentation liquor of the recombinant rhodococcus erythropolis by using the seed liquor.
In a specific example, the fermentation medium for preparing the fermentation broth of the recombinant rhodococcus erythropolis comprises glucose 10 g/L-50 g/L, urea 5 g/L-20 g/L, yeast extract 1 g/L-4 g/L, peptone 1 g/L-10 g/L, KH 2 PO 4 0.2 g/L -3 g/L,K 2 HPO 4 0.2 g/L -3 g/L,MgSO 4 ·7H 2 O0.2 g/L-3 g/L, monosodium glutamate 1 g/L and CoCl 2 0.03 mM-0.5 mM, pH 7.0-7.5.
And (3) carrying out hydration reaction on the fermentation liquor and acrylonitrile or 3-cyanopyridine to synthesize acrylamide or nicotinamide.
Embodiments of the present application will be described in detail below with reference to examples. It should be understood that these examples are illustrative only of the present application and are not intended to limit the scope of the present application. The experimental methods, in which specific conditions are not noted in the following examples, are preferably referred to in the guidelines given in the present application, may be according to the experimental manual or conventional conditions in the art, may be according to the conditions suggested by the manufacturer, or may be referred to experimental methods known in the art.
In the specific examples described below, the measurement parameters relating to the raw material components, unless otherwise specified, may have fine deviations within the accuracy of weighing. Temperature and time parameters are involved, allowing acceptable deviations from instrument testing accuracy or operational accuracy.
EXAMPLE 1 annotation of carotenoid synthesis-related genes of Rhodococcus rhodochrous
Rhodococcus erythropolis (CN 101663389A) was cultured in LB medium, and then the cells were collected, and subjected to three-generation genome sequencing by Jin Weizhi Biotech Co, using a RAST server(http:// rast. Nmpdr. Org /) the genome was annotated analytically, and the KEGG and GO databases were compared to determine its carotenoid-producing metabolic pathways. The major relevant genes include 2 genes encoding GGPP (geranylgeranyl pyrophosphate, geranylgeranyl pyrophosphat) synthetases (designated respectivelycrtE-1 and crtE-2The DNA sequences are shown as SEQ ID NO. 1 and SEQ ID NO. 2, respectively), 1 gene encoding phytoene dehydrogenase (designated ascrtIThe DNA sequence is shown as SEQ ID NO: 3), 1 gene (named ascrtMThe DNA sequence is shown as SEQ ID NO. 4), 1 gene encoding phytoene synthase (namedcrtBThe DNA sequence is shown as SEQ ID NO. 5), 1 code lycopene beta-cyclase (namedcrtYThe DNA sequence is shown as SEQ ID NO: 6).
The partial synthesis pathway of beta-carotene and the distribution of the above genes are shown in FIG. 1,crtE-1、crtI、crtM、 crtBthe 4 genes are adjacent and are in the same gene cluster; whilecrtE-2、crtYAre far away from other genes and are independent.
The analysis of the gene annotation also confirms the redundancy of the rhodococcus gene. There are two genes encoding GGPP synthetases, and in particular which one plays a major role in carotenoid synthesis, yet to be analyzed.
Example 2 inhibition of carotenoid synthesis-related genes of rhodococcus erythropolis Using CRISPRi technology
In the embodiment, a CRISPRi system is constructed on the basis of a rhodococcus double-plasmid CRISPR gene knockout system (CN 110499274A) for inhibiting the carotene genes of the rhodococcus.
First, pNV-Pa2-dCAS9 was constructed as follows: pNV-Pa2-Cas9 (CN 110499274A) was digested with XbaI and KpnI to give plasmid backbone; using pNV-Pa2-Cas9 as a template, and using primers D10A-F and H840A-R, and amplifying the primers H840A-F and dCAS9-R to obtain two gene fragments; gibson ligation of the gene fragment and plasmid backbone resulted in pNV-Pa2-dCAs9, i.e., two mutations D10A and H840A were introduced into the Cas9 protein to make it lose nuclease activity, but retain DNA binding capacity.
Targeting was designed using the http:// www.rgenome.net/cas-designer/websitecrtE-1、crtE-2、crtI、crtEM、crtB5 genes of sgRNA, synthesizing primers, and constructing plasmid of pBNVCm-sgRNA series, concretely comprising the following steps: plasmid pBNVCm-sgRNA is digested with BbsI to obtain a plasmid backbone; the primers crtE-1-F and crtE-1-R, crtE-2-F and crtE-2-R, crtI-F and crtI-R, crtM-F and crtM-R, crtB-F and crtB-R, crtY-F and crtY-R are denatured at 95 ℃ respectively, and gradually cooled to 25 ℃ at 0.1 ℃/s, and the two primers are paired with each other to form dsDNA with sticky ends; the dsDNA was ligated to the plasmid backbone using T4 DNA ligase to give plasmids pBNVCm-crtE1-sgRNA, pBNVCm-crtE2-sgRNA, pBNVCm-crtI-sgRNA, pBNVCm-crtM-sgRNA, pBNVCm-crtB-sgRNA, pBNVCm-crtY-sgRNA targeting different genes.
Plasmids such as pBNVCm-crtE1-sgRNA, pBNVCm-crtE2-sgRNA, pBNVCm-crtI-sgRNA, pBNVCm-crtM-sgRNA, pBNVCm-crtB-sgRNA, pBNVCm-crtY-sgRNA and the like are respectively and simultaneously introduced into rhodococcus erythropolis with pNV-Pa2-dCAs9, so that recombinant strains which inhibit different carotene synthesis genes are obtained and are named as TH-crtE1, TH-crtE2, TH-crtI, TH-crtM, TH-crtB and TH-crtY respectively. The plasmids pBNVCm-sgRNA and pNV-Pa2-dCAs9 which do not target any genes are simultaneously introduced into rhodococcus erythropolis, and then a control strain TH-control is obtained.
The sequences of the primers used in this example are shown in Table 1, wherein the underlined parts are the recognition sequences of the designed sgRNAs.
TABLE 1 primers and sequences used in example 1
Example 3 determination of OD of recombinant rhodococcus erythropolis 460 Values and carotenoid content and nitrile hydratase Activity
Recombinant bacteria TH-crtE1, TH-crtE2, TH-crtI, TH-crtM, TH-crtB, TH-crtY and TH-control were inoculated into seed medium (glucose 10-50 g/L, yeast extract 1-4g/L, peptone 1-10g/L, KH) to which 25. Mu.g/mL kanamycin and 5. Mu.g/mL chloramphenicol were added, respectively 2 PO 4 0.2-3 g/L,K 2 HPO 4 0.2-3 g/L,MgSO 4 ·7H 2 O0.2-3 g/L, monosodium glutamate 1-g/L, pH 7.5), 25-37 ℃ and 100-200 rpm for 48 hours, transferring to fermentation medium (glucose 10-50 g/L, urea 5-20 g/L, yeast extract 1-4g/L, peptone 1-10g/L, KH) according to 10% proportion 2 PO 4 0.2-3 g/L,K 2 HPO 4 0.2-3 g/L,MgSO 4 ·7H 2 O0.2-3 g/L, monosodium glutamate 1 g/L, coCl 2 0.03-0.5mM, pH 7.5), fermenting at 28deg.C and 200rpm for 48 hr to obtain bacterial liquid, and measuring OD by using spectrophotometer 460 And the nitrile hydratase activity (method reference CN107177581 a) and carotenoid content were determined. The carotenoid determination method specifically comprises the following steps: 1mL of the fermentation broth was centrifuged at 10000 Xg for 3 minutes, and then the cells were collected, suspended with distilled water, centrifuged again, resuspended with 1mL of acetone, and then heated at 55℃for 15 minutes with light cut off, and centrifuged at 10000 Xg for 10 minutes, and the absorbance of the supernatant at 475nm was measured using acetone as a blank reference. The carotenoid yield (mg/L) was calculated according to the following formula: c= 3.994a 454 。
OD after 48 hours of fermentation of several different recombinant bacteria 460 The nitrile hydratase enzyme activity and carotenoid production are shown in FIGS. 2, 3 and 4, respectively.
Inhibition ofcrtMOD of Rhodococcus 460 Reduced by 33%, reduced by 49% in enzyme activity,crtMthe encoding membrane protein gene, and the reduction of the expression level thereof may affect the growth of rhodococcus. While suppressingcrtE1、crtE2、crtIAndcrtBthe gene has little influence on the growth and enzyme production of the rhodococcus; wherein inhibition is inhibitedcrtE1Has effect in promoting growth and enzyme production, and can make OD 460 The enzyme activity of the nitrile hydratase is improved by 11 percent and 6 percent.
Inhibition of crtE2 and crtY had no significant effect on carotenoid production, while inhibition was inhibitedcrtE1、crtI、crtMAndcrtBthe carotenoid production can be reduced to various degrees, wherein inhibition is achievedcrtE1The effect is most remarkable, and the yield of carotenoid is reduced by 97.5%. It was found that in rhodococcus erythropolis, two genes encoding GGPP synthase were presentcrtE1AndcrtE2in,crtE1plays a major role in the synthesis of carotenoids.
From the aspects of cell growth, enzyme production, carotenoid reduction and the like, TH-crtE1 is the optimal recombinant bacterium. By comparing TH-control with TH-crtE1, it can be seen that the control bacteria are orange in color, while TH-crtE1 appears white, as shown in FIG. 5. This was also the first reported white "rhodococcus".
EXAMPLE 4 recombinant Rhodococcus rhodochrous catalyzed hydration of acrylonitrile to acrylamide
400mL of cell suspensions of recombinant bacteria TH-control and TH-crtE1 (bacterial concentration 1.5 gdcw/L) were taken and placed in a 1L three-necked flask, and hydration reaction was performed under ice bath conditions. And (3) dropwise adding acrylonitrile while stirring, controlling the reaction temperature to be 18-25 ℃, stopping dropwise adding the acrylonitrile when the concentration of the acrylamide reaches 50%, and continuously reacting for 1 hour to completely consume the acrylonitrile. The reaction mixture was centrifuged at 10000 Xg for 20 minutes to separate the cells, thereby obtaining an acrylamide solution as a product.
The color of the acrylamide solution is recorded by photographing, as shown in fig. 6, the carotenoid content of the control bacterium TH-control is higher, and a large amount of pigment is released in the hydration reaction process, so that the color of the product solution is darker; in comparison, the color of the product solution synthesized by the recombinant bacteria TH-crtE1 is lighter, and the product quality is obviously improved.
Example 5 knockout of the carotenoid synthesis-related Gene of Rhodococcus rhodochrous
The CRISPRi technology is adopted to inhibit carotenoid synthesis related genes, and exogenous plasmids are required to be introduced, so that on one hand, the physiological burden of rhodococcus is increased; on the other hand, plasmids have the problem of being lost due to unstable passage. For industrial production, it is necessary to knock out carotenoid synthesis related genes and construct strains with stable performance. Based on the results of example 3, in the carotenoid synthesis-related gene,crtE-2、crtYhas no effect on reducing pigment contentcrtMThe inhibition of (2) affects the growth of rhodococcus erythropolis, so the gene knockout of this example is aimed atcrtE-1AndcrtI。
knocking out by adopting homologous recombination double exchange methodcrtE-1AndcrtIspecifically, the following is described.
Construction of plasmid pK18mobsacB-crt for suicide: commercial plasmid pK18mobsacBHindIIIXbaI, enzyme cutting to obtain a framework; using red rhodococcus as template, using crt-up-F, crt-up-R to amplify upstream homology arm, using primer crt-down-F, crt-down-R to amplify downstream homology arm; the three were joined by Gibson to give pK18mobsacB-crt.
The pK18mobsacB-crt is subjected to electric excitation transformation to red rhodococcus, and after resuscitating culture, the red rhodococcus is coated on LB plates containing 25 mug/mL kanamycin, and integrated into the genome by single exchange; single-exchanged colonies were further plated on LB plates of 100 g/L sucrose, grown for 3 days at 28℃to give colonies, and distinguished by colony PCR and colony colorcrtE-1AndcrtIwhether the gene was successfully knocked out, and the successfully knocked out colony was named as TH-Deltacrt. And inhibitcrtE1The recombinant strain TH-crtE1 of the gene is similar, and the thallus of the TH-delta crt is white, so that the synthesis path of carotenoid can be judged to be blocked.
The primers used in this example are shown in Table 2.
TABLE 2 primers and sequences used in example 5
Example 6 determination of growth of recombinant TH-Deltacrt and nitrile hydratase Activity
Inoculating recombinant bacteria TH-Deltacrt, TH-crtE1 into seed culture medium (glucose 10-50 g/L, yeast extract 1-4g/L, peptone 1-10g/L, KH) containing no antibiotics, kanamycin 25 μg/mL and chloramphenicol 5 μg/mL, respectively 2 PO 4 0.2-3 g/L,K 2 HPO 4 0.2-3 g/L,MgSO 4 ·7H 2 O0.2-3 g/L, monosodium glutamate 1-g/L, pH 7.5), 25-37 ℃ and 100-200 rpm for 48 hours, transferring to fermentation medium (glucose 10-50 g/L, urea 5-20 g/L, yeast extract 1-4g/L, peptone 1-10g/L, KH) according to 10% proportion 2 PO 4 0.2-3 g/L,K 2 HPO 4 0.2-3 g/L,MgSO 4 ·7H 2 O0.2-3 g/L, monosodium glutamate 1 g/L, coCl 2 0.03-0.5mM, pH value7.5 Fermentation culture at 28℃and 200rpm for 48 hours to obtain a bacterial liquid, and measurement of OD by using a spectrophotometer 460 And the nitrile hydratase activity (method reference CN 107177581A) and carotenoid production were measured.
OD of two recombinant bacteria 460 And the nitrile hydratase activity is shown in Table 3, compared with TH-crtE1, the growth of recombinant strain TH-Deltacrt with the carotenoid synthesis gene knocked out is almost unchanged, the carotenoid yield is further reduced by 57%, and the nitrile hydratase activity is improved by 21%. The reason for this is that recombinant TH-Deltacrt does not contain exogenous plasmid, and more cell resources can be used for expression of nitrile hydratase.
TABLE 3 OD of TH-crtE1 and TH- Δcrt 460 Comparison of nitrile hydratase Activity
The technical features of the above-described embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above-described embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The above examples merely represent a few embodiments of the present application, which are described in more detail and are not to be construed as limiting the scope of the invention. It should be noted that it would be apparent to those skilled in the art that various modifications and improvements could be made without departing from the spirit of the present application, which would be within the scope of the present application. The scope of the patent is, therefore, indicated by the appended claims, and the description may be used to interpret the contents of the claims.
Claims (12)
1. A recombinant rhodococcus erythropolis, wherein a carotenoid synthesis gene in said recombinant rhodococcus erythropolis is reduced in expression or knocked out; the carotenoid synthesis genes with reduced expression or knockdown include genes encoding GGPP synthasecrtE-1Tomato encoded with octahydroGene of erythrosin dehydrogenasecrtIGene encoding carotene synthesis-related membrane proteincrtMAnd genes encoding phytoene synthasecrtBAt least one of (2).
2. The recombinant rhodococcus erythropolis of claim 1, wherein the carotenoid synthesis gene that reduces expression or knocks out comprises a gene encoding GGPP synthetasecrtE-1And/or genes encoding phytoene dehydrogenasecrtI。
3. The recombinant rhodococcus erythropolis of claim 1 or 2, wherein the knockout comprises a knockout of part or all of the carotenoid synthesis gene.
4. The recombinant rhodococcus erythropolis of claim 3, wherein the gene encoding GGPP synthetasecrtE-1The nucleotide sequence of the gene is shown as SEQ ID NO. 1, and the gene for encoding phytoene dehydrogenasecrtIThe nucleotide sequence of the gene is shown as SEQ ID NO. 3, and the gene for encoding the carotene synthesis related membrane proteincrtMThe nucleotide sequence of the gene is shown as SEQ ID NO. 4, and the gene for encoding phytoene synthetasecrtBThe nucleotide sequence of (2) is shown as SEQ ID NO. 5.
5. The recombinant rhodococcus erythropolis of claim 3, wherein the method of knocking out the carotenoid synthesis gene comprises a homologous recombination double crossover method.
6. The recombinant rhodococcus erythropolis of claim 5, wherein the method for constructing the recombinant rhodococcus erythropolis using the homologous recombination double crossover method comprises the steps of:
connecting an upstream homologous sequence and a downstream homologous sequence of a carotenoid synthesis gene into a suicide plasmid vector to obtain a recombinant suicide plasmid vector;
and (3) introducing the recombinant suicide plasmid vector into rhodococcus, and screening to obtain recombinant rhodococcus.
7. The recombinant rhodococcus erythropolis of claim 1 or 2, wherein the method of reducing carotenoid synthesis gene expression comprises one or more of CRISPRi technology, antisense RNA technology, RNA interference technology and promoter attenuation method.
8. The recombinant rhodococcus erythropolis of claim 7, wherein the method of constructing the recombinant rhodococcus erythropolis using the CRISPRi technique comprises introducing a vector comprising dCas9 gene and a vector comprising sgRNA targeting carotenoid synthesis gene into the rhodococcus erythropolis to construct the recombinant rhodococcus erythropolis.
9. The use of the recombinant rhodococcus erythropolis of any one of claims 1 to 8 in the synthesis of compounds comprising one or more of amide compounds, carboxylic acid compounds, chiral epoxides and chiral amine compounds.
10. Use according to claim 9, wherein the amide-type compound comprises acrylamide and/or nicotinamide.
11. Use according to claim 10, characterized in that the method of acrylamide or nicotinamide synthesis comprises the following steps: expressing a nitrile hydratase by using the genome of the recombinant rhodococcus erythropolis and/or expressing a nitrile hydratase by introducing an exogenous plasmid carrying a gene encoding a nitrile hydratase into the recombinant rhodococcus erythropolis;
and catalyzing acrylonitrile or 3-cyanopyridine hydration reaction by using the nitrile hydratase to synthesize acrylamide or nicotinamide.
12. The use according to claim 11, wherein the temperature of the hydration reaction is 15 ℃ to 45 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311553921.6A CN117264865B (en) | 2023-11-21 | 2023-11-21 | Recombinant rhodococcus erythropolis and application thereof in compound synthesis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311553921.6A CN117264865B (en) | 2023-11-21 | 2023-11-21 | Recombinant rhodococcus erythropolis and application thereof in compound synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117264865A true CN117264865A (en) | 2023-12-22 |
CN117264865B CN117264865B (en) | 2024-03-12 |
Family
ID=89216382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311553921.6A Active CN117264865B (en) | 2023-11-21 | 2023-11-21 | Recombinant rhodococcus erythropolis and application thereof in compound synthesis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117264865B (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253663A1 (en) * | 2003-06-12 | 2004-12-16 | Qiong Cheng | Genes encoding carotenoid compounds |
US20050014219A1 (en) * | 2003-05-07 | 2005-01-20 | Qiong Cheng | Genes encoding carotenoid compounds |
WO2005010156A2 (en) * | 2003-07-17 | 2005-02-03 | E.I. Dupont De Nemours And Company | Genes encoding carotenoid compounds |
CN1607253A (en) * | 1995-06-09 | 2005-04-20 | Dsmip资产公司 | Fermentative carotenoid production |
WO2006096392A2 (en) * | 2005-03-04 | 2006-09-14 | Diversa Corporation | Enzymes involved in astaxanthin, carotenoid and isoprenoid biosynthetic pathways, genes encoding them and methods of making and using them |
US20090093015A1 (en) * | 2007-10-09 | 2009-04-09 | Kemin Foods, L.C. | Beta-cryptoxanthin production using a novel lycopene beta-monocyclase gene |
CN101432436A (en) * | 2004-08-16 | 2009-05-13 | 纳幕尔杜邦公司 | Carotenoid hydroxylase enzymes |
CN101663389A (en) * | 2008-03-24 | 2010-03-03 | 清华大学 | An amidase gene knock-out engineered strain for nitrile hydratase production, its construction and application |
CN104805167A (en) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | Method for producing beta-carotene, and genetically engineered bacterium thereof |
CN108611360A (en) * | 2018-05-14 | 2018-10-02 | 陕西师范大学 | A kind of production lycopene hydrogenlike silicon ion engineered strain and its construction method |
CN110499274A (en) * | 2019-09-18 | 2019-11-26 | 清华大学 | A kind of genetic engineering Rhodococcus sp and its construction method and application |
WO2022221338A2 (en) * | 2021-04-12 | 2022-10-20 | Washington University | Systems, microorganisms, or methods for waste pet valorization |
-
2023
- 2023-11-21 CN CN202311553921.6A patent/CN117264865B/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1607253A (en) * | 1995-06-09 | 2005-04-20 | Dsmip资产公司 | Fermentative carotenoid production |
US20050014219A1 (en) * | 2003-05-07 | 2005-01-20 | Qiong Cheng | Genes encoding carotenoid compounds |
US20040253663A1 (en) * | 2003-06-12 | 2004-12-16 | Qiong Cheng | Genes encoding carotenoid compounds |
WO2005010156A2 (en) * | 2003-07-17 | 2005-02-03 | E.I. Dupont De Nemours And Company | Genes encoding carotenoid compounds |
CN101432436A (en) * | 2004-08-16 | 2009-05-13 | 纳幕尔杜邦公司 | Carotenoid hydroxylase enzymes |
WO2006096392A2 (en) * | 2005-03-04 | 2006-09-14 | Diversa Corporation | Enzymes involved in astaxanthin, carotenoid and isoprenoid biosynthetic pathways, genes encoding them and methods of making and using them |
US20090093015A1 (en) * | 2007-10-09 | 2009-04-09 | Kemin Foods, L.C. | Beta-cryptoxanthin production using a novel lycopene beta-monocyclase gene |
CN101663389A (en) * | 2008-03-24 | 2010-03-03 | 清华大学 | An amidase gene knock-out engineered strain for nitrile hydratase production, its construction and application |
CN104805167A (en) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | Method for producing beta-carotene, and genetically engineered bacterium thereof |
CN108611360A (en) * | 2018-05-14 | 2018-10-02 | 陕西师范大学 | A kind of production lycopene hydrogenlike silicon ion engineered strain and its construction method |
CN110499274A (en) * | 2019-09-18 | 2019-11-26 | 清华大学 | A kind of genetic engineering Rhodococcus sp and its construction method and application |
WO2022221338A2 (en) * | 2021-04-12 | 2022-10-20 | Washington University | Systems, microorganisms, or methods for waste pet valorization |
Non-Patent Citations (3)
Title |
---|
L. TAO等: "Novel b-carotene ketolases from non-photosynthetic bacteria for canthaxanthin synthesis", MOL GEN GENOMICS, 9 November 2004 (2004-11-09), pages 530 * |
TAO, L等: "Metabolic engineering for synthesis of aryl carotenoids in Rhodococcus. Applied microbiology and biotechnology", APPLIED GENETICS AND MOLECULAR BIOTECHNOLOGY, vol. 70, pages 222 - 228 * |
邱孜博;汪荣;张杨;吴茜;谢笔钧;杨季芳;陈吉刚;孙智达;: "红球菌及其生物降解作用研究进展", 食品科学, no. 07, pages 254 - 258 * |
Also Published As
Publication number | Publication date |
---|---|
CN117264865B (en) | 2024-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113684164B (en) | Construction method and application of microorganism for high-yield lactoyl-N-neotetraose | |
EP4288446A1 (en) | Improved biotechnological method for producing guanidino acetic acid (gaa) by inactivation of an amino acid exporter | |
WO2023011576A1 (en) | Method for constructing microorganism with high yield of lactoyl-n-tetrasaccharide, and application | |
Spadiut et al. | Evaluation of different expression systems for the heterologous expression of pyranose 2-oxidase from Trametes multicolor in E. coli | |
CN104388457A (en) | Gene modification method for increasing yield of phloroglucinol and application of same | |
CN103328498B (en) | New O-acetylhomoserine sulfhydrylase or its mutant protein, and use it to change into the method for methionine(Met) | |
CN113604472B (en) | CRISPR/Cas gene editing system applied to Trichoderma reesei | |
CN104789586B (en) | Genome of E.coli integration vector, genetic engineering bacterium and the application in xylitol is produced | |
CN107287144B (en) | Metabolically-modified bacillus subtilis biotransformation cell and preparation method and application thereof | |
CN117264865B (en) | Recombinant rhodococcus erythropolis and application thereof in compound synthesis | |
US11492607B2 (en) | Highly active S-cyanohydrin lyase and application thereof | |
CN116333953A (en) | Genetically engineered bacterium for high-yield cytidine and application thereof | |
CN115747229A (en) | Heme biosensor-based growth coupling high-throughput screening method and application thereof in multi-gene metabolic pathway optimization | |
CN110878293B (en) | Application of bacillus licheniformis with deletion of yceD gene in production of heterologous protein | |
CN114058606A (en) | Application of bacillus licheniformis with deleted xpt gene in production of heterologous protein | |
WO2017212030A1 (en) | Methods of producing astaxanthin or precursors thereof | |
CN102061290B (en) | Method for realizing over expression of thermostable laccase gene through location transformation | |
CN106929527A (en) | A kind of genetic engineering bacterium of phloroglucin synthesis capability high and construction method and application | |
US20230002796A1 (en) | Method for inducing microbial mutagenesis to produce lactic acid | |
Shin et al. | An integrative approach to improving the biocatalytic reactions of whole cells expressing recombinant enzymes | |
CN110872595A (en) | Acid-resistant expression cassette and application thereof in organic acid production by fermentation | |
CN111979257A (en) | Recombinant DNA and application thereof | |
CN116286923B (en) | Ribosome binding sequence screening and application thereof in construction of inositol recombinant bacteria | |
JP2006075097A (en) | Transformant having carotenoid productivity and method for producing carotenoid | |
CN115976058B (en) | Toxin gene and application thereof in construction of recombinant and/or gene-edited engineering bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |